Neural Development and Stem Cells
Mahendra S. Rao
Sold by AHA-BUCH GmbH, Einbeck, Germany
AbeBooks Seller since August 14, 2006
New - Soft cover
Condition: New
Quantity: 1 available
Add to basketSold by AHA-BUCH GmbH, Einbeck, Germany
AbeBooks Seller since August 14, 2006
Condition: New
Quantity: 1 available
Add to basketDruck auf Anfrage Neuware - Printed after ordering - This expanded and updated edition reflects the enormous increase in our knowledge of the development of the nervous system and the use of neural stem cells in clinical applications. Integrating new information about the use of development of neural stem cells for clinical applications, Drs. Rao, Carpenter and Vemuri have added additional chapters on neural transplantation and development of neural stem cells using reprogramming technologies. A new chapter on cancer in nervous system delineates how the fundamental biology of neural stem cells informs our understanding of cancer and tumor formation in the nervous system. Special attention is paid to the derivation of neural cells from embryonic stem cells and induced pluripotent stem cells. Authoritative and up-to-date, Neural Development and Stem Cells, 3rd Edition provides neuroscientists with a handy guide to stem cells in the nervous system, tracing with great clarity the development of stem cells from differentiation to neurons, astrocytes, and oligodendrocytes.
Seller Inventory # 9781489996206
Mahendra S. Rao, MD, Ph.D
Dr. Rao is internationally renowned for his research involving human embryonic stem cells (hESCs) and other somatic stem cells. He has worked in the stem cell field for more than 20 years, with stints in academia, government and regulatory affairs and industry. He received his M.D. from Bombay University in India and his Ph.D. in developmental neurobiology from the California Institute of Technology, Pasadena. Following postdoctoral training at Case Western Reserve University, Cleveland, he established his research laboratory in neural development at the University of Utah, Salt Lake City. He next joined the National Institute on Aging as chief of the Neurosciences Section, where he studied neural progenitor cells and continued to explore his longstanding interest in their clinical potential. He then spent six years as the vice president of Regenerative Medicine at Life Technologies, Carlsbad, Calif. Most recently, he returned in August 2011 tothe National Institutes of Health (NIH), as Director of the new NIH Center for Regenerative Medicine (NIH CRM). He co-founded Q Therapeutics, a neural stem cell company based in Salt Lake City. He also served internationally on advisory boards for companies involved in stem cell processing and therapy, on committees including the U.S. Food and Drug Administration’s Cellular Tissue and Gene Therapies Advisory Committee chair, and as the California Institute of Regenerative Medicine and International Society for Stem Cell Research liaison to the International Society for Cellular Therapy.
Melissa Carpenter, Ph. D.
For the last 17 years, Dr. Carpenter has worked on the development of cell therapies using human adult and embryonic stem cells, in academia and industry, in the United States and Canada. She has been involved with human embryonic stem cell (hESC) research since the field was established. Her work involves discovery research and the translation ofthis research into therapeutics, including developing strategies for preclinical development and navigating the regulatory issues surrounding stem cell therapies. She has held leadership positions at 3 of the major stem cell companies: CytoTherapeutics, Inc (StemCells, Inc), Geron, Corp., and Novocell, Inc (Viacyte, Inc). Currently Dr. Carpenter is President of Carpenter Group Consulting and works with early stage companies, academic groups and investors to translate discovery based research into stem cell therapies. She is credited with numerous publications and patents in the stem cell field.
Mohan C. Vemuri, Ph.D.
Dr. Vemuri is currently the Director, Research and Development of Stem Cells and Regenerative Medicine at Life Technologies. He has been with the company since 2006 in different R&D leadership roles and instrumental in stem cell based product development for human pluripotent (embryonic and iPSC) and adult stem cells in cGMP regulatedconditions for research and cell therapy. Dr. Vemuri has served as faculty and staff at Children’s Hospital of Philadelphia (University of Pennsylvania) and worked on enhancing hematopoietic stem cell engraftment and immune reconstitution utilizing gene engineering technology. Dr. Vemuri was also responsible for designing stem cell based assays and lead drug discovery effort for Parkinson’s disease in GLP settings at Thomas Jefferson University. Dr. Vemuri is a recipient of National Institutes of Health Fogarty Fellowship award and best investigator award and a citation for deriving hESC from the Association of Reproductive Medicine for the year 2005. Dr. Vemuri has held scientific positions in University of Hyderabad, Thomas Jefferson University, and University College of Sciences in Philadelphia. Dr. Vemuri has authored over 50 publications in peer reviewed journals, and edited three books,1) Stem Cell Assays 2. Regulatory Networks in Stem Cells and 3., MSC Assays and Applications, by Springer/Humana Press. Dr. Vemuri presently works and collaborates with different investigators towards the successful utilization of stem cells in regenerative cell therapies in a regulatory compliant environment."About this title" may belong to another edition of this title.
General Terms and Conditions and Customer Information / Privacy Policy
I. General Terms and Conditions
§ 1 Basic provisions
(1) The following terms and conditions apply to all contracts that you conclude with us as a provider (AHA-BUCH GmbH) via the Internet platforms AbeBooks and/or ZVAB. Unless otherwise agreed, the inclusion of any of your own terms and conditions used by you will be objected to
(2) A consumer within the meaning of the following regulations is any natural person who concludes...
We ship your order after we received them
for articles on hand latest 24 hours,
for articles with overnight supply latest 48 hours.
In case we need to order an article from our supplier our dispatch time depends on the reception date of the articles, but the articles will be shipped on the same day.
Our goal is to send the ordered articles in the fastest, but also most efficient and secure way to our customers.
| Order quantity | 30 to 40 business days | 7 to 14 business days |
|---|---|---|
| First item | US$ 72.91 | US$ 84.50 |
Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.